The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment

Yale University

Status: Completed

Conditions: HIV Positive; HIV Infections; Opioid Agonist Treatment; Opioid Dependence

Study type: Observational

Funder types: Other

Identifiers

NCT00857350

0709003082

Details and patient eligibility

About

HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses:

1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%.
2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.

Enrollment: 60 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HIV+
• Opioid dependent
• Receiving methadone or buprenorphine for at least one month

Exclusion criteria

• age < 18 years
• current dementia;
• inability to read or understand English
• inability to provide written informed consent

Trial design

60 participants in 1 patient group

HIV+, opiod dependent